This version of the Guidance has been updated to reflect several key developments as indicated below. Updated references have been provided throughout the Guidance.
Global Changes Occurring throughout the document:
- RAV changed to RAS
- Standardized renal function parameter from CrCI to eGFR
Initial Treatment:
- Includes new recommendation to shorten the duration of ledipasvir (90 mg)/sofosbuvir (400 mg) in patients without cirrhosis to 8 weeks for non-black, HIV-uninfected, and whose HCV RNA is <6 million IU/mL
- Updated grading of sofosbuvir/velpatasvir for genotypes 5 and 6
- Language added related to recent data regarding 8 weeks of PrOD for genotype 1b with early stage fibrosis
Retreatment:
Decompensated:
Renal:
Upcoming Updates:
- Guidance will be forthcoming regarding treatment of adolescents living with chronic HCV given recent FDA-approvals